English | 中文
UserName:
Password: 
 
Vital Therapies, Inc. (VTI) is developing the first human liver cell-based Extracorporeal Liver Assist Devic (ELAD.).  ELAD provides metabolic support for patients with severe liver failure by processing toxins and synthesizing proteins that are key products of normal human liver function.  The WHO identified the worldwide market for acute-on-chronic liver failure at approximately 12 million patients. In China alone there are over 400,000 deaths each year from liver disease.  VTI has completed a successful pivotal trial and filed for market approval in China ...
Index>> News Summary
Cyborg Therapy
Doctors test latest attempt at artificial liver
VTI Is Shipping ELAD to China (Source from: Health of Sohu.com)
A New Hope for Patients of Sever Liver Failure: An Innovative Liver Disease Therapy
China’s Clinical Trial Under Way: The First Ever Human Cell-Based System of The World
USA MGH Liver machine rejuvenates patient
6information in total 20/Page this1/1Page     Page